Business, energy, technology, markets and global industry news from Business News Today

acute myeloid leukemia

PharmaDeviceNews acute myeloid leukemia
Pharma & Biotech

SELLAS Life Sciences prepares pancreatic cancer SLS009 data for AACR 2026

SELLAS investors await event-driven Phase 3 AML results while SLS009 heads to AACR with preclinical pancreatic cancer combination data.

Read More
Orum’s ORM-1153 is moving toward an approximately 42-patient Phase 1 study after FDA clearance, testing whether a CD123-targeting conjugate can selectively deliver a GSPT1 protein degrader into acute myeloid leukemia cells and translate targeted protein degradation into a new precision-oncology strategy. Representative image.
Pharma & Biotech

Orum takes ORM-1153 into human testing after FDA clears first-in-human AML study

Orum plans an approximately 42-patient Phase 1 study of ORM-1153 after FDA cleared the CD123-targeting conjugate to deliver a GSPT1 protein degrader into AML cells.

Read More
Sumitomo Pharma’s investigational menin inhibitor enzomenib gains FDA orphan drug designation as development advances for acute lymphoblastic leukemia. Representative image.
Pharma & Biotech

Sumitomo Pharma’s enzomenib receives FDA orphan drug designation for acute lymphoblastic leukemia

FDA orphan drug status expands enzomenib’s ALL pathway as Sumitomo Pharma advances pivotal development in biomarker-defined acute leukemia.

Read More
Representative image: Hematology researchers analyze blood samples as Moleculin’s $MBRX MIRACLE trial reports a 37% blinded composite remission rate in relapsed or refractory acute myeloid leukemia, including patients who previously failed venetoclax.
Pharma & Biotech

New MIRACLE data examine remission after venetoclax failure in relapsed AML

MIRACLE reports a 37% blinded composite remission rate in relapsed AML, including patients who previously failed venetoclax treatment.

Read More
Representative image: Clinicians prepare a donor-derived cell therapy infusion as TScan Therapeutics’ $TCRX TSC-101 enters the Phase 3 ALLOHA-2 trial to prevent AML and MDS relapse after stem cell transplantation.
Pharma & Biotech

TSC-101 enters pivotal ALLOHA-2 trial after early donor-chimerism results

TSC-101 enters the Phase 3 ALLOHA-2 trial to test whether donor-derived TCR-T therapy can prevent AML and MDS relapse after transplant.

Read More
Pharma & Biotech

Why Blood Cancer United’s luveltamab move could change rare pediatric cancer access

Find out how Blood Cancer United’s luveltamab access move could reshape rare pediatric AML drug rescue models.

Read More
Representative image: Actinium Pharmaceuticals’ ATNM-400 update and new Actimab-A and Iomab-ACT patent allowances underscore rising investor and clinical interest in targeted radiotherapy, actinium-225 cancer treatments and next-generation radiopharmaceuticals.
Pharma & Biotech

Actinium’s radiotherapy push gains IP depth as ATNM-400 heads to SNMMI 2026

Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.

Read More
Pharma & Biotech

Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?

Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.

Read More
Representative image of acute myeloid leukemia research, illustrating how Orum Therapeutics’ ORM-1153 AACR 2026 data are drawing attention to CD123-targeting degrader-antibody conjugates in AML.
Pharma & Biotech

Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention

Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.

Read More
Pharma & Biotech

How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML

Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.

Read More